10-Q quarterly report · filed Nov 4, 2026

Charles River Laboratories (CRL) Q3 2026 10-Q Quarterly Report

Short answer

Charles River Laboratories (CRL) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 26, 2026. Quarterly revenue was $983M (down 2.2% year over year) with net income of $333M.

Q3 2026 key financials · XBRL

Revenue
$983M
−2.2% YoY · −2.1% QoQ
Net income
$333M
+512.0% YoY · +22574.2% QoQ
Operating margin
20.6%
EPS (diluted)
$6.82
+520.0% YoY · +17150.0% QoQ

Source: XBRL data from the Charles River Laboratories (CRL) Q3 2026 10-Q on SEC EDGAR. USD.

Charles River Laboratories Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $982.7M, down $22.1M or 2.2% YoY
  • Operating margin 20.6% vs 13.3% YoY, operating income $202.6M vs $133.8M
  • Best segment: Manufacturing revenue $178.9M, operating margin 35.7% vs 20.9%
  • Worst segment: RMS revenue $207.5M, down 2.8% YoY, driven by Cell Solutions divestiture
  • Cash $200.4M vs $213.8M, operating cash flow $474.9M vs $590.1M, $300.0M stock repurchases and $467.3M acquisitions through nine months

Risk Factors

  • No material changes to 2025 Form 10-K risk factors
  • Q1 10-Q risk factor incorporated by reference, with no details repeated this quarter
  • Additional unknown or currently immaterial risks could materially adversely affect results

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Charles River Laboratories quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.